However, a challenge in using VSV encoding p53 is that p53 activation can induce antiviral responses in some tumor types with active type I IFN signaling, leading to VSV attenuation in tumor tissues and decreased oncolytic abilities of VSV. The gene discussed is TP53; the disease is neoplasm.